GPCRs as potential therapeutic targets in preeclampsia

Drug Discovery Today: Disease Models

Volumn 9, Issue 3, 2012, Pages

  McGuane, J T ^a,b   Conrad, K P ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; BRADYKININ B2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; MAS RECEPTOR; RECEPTOR; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RELAXIN; RELAXIN RECEPTOR RXFP1; UNCLASSIFIED DRUG;

ARTICLE; HEART ATRIUM PRESSURE; HUMAN; HYPERTENSION; NONHUMAN; PREECLAMPSIA; PREGNANCY; PROTEIN EXPRESSION; VASOCONSTRICTION; VASODILATATION;

EID: 84871438596     PISSN: None     EISSN: 17406757     Source Type: Journal    
DOI: 10.1016/j.ddmod.2012.05.001     Document Type: Review

References (99)

1. Chapman, A.B. et al. (1998) Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int. 54, 2056-2063
2. Robson, S.C. et al. (1989) Serial study of factors influencing changes in cardiac output during human pregnancy. Am. J. Physiol. 256, H1060-H1065
3. Conrad, K.P. (2011) Maternal vasodilation in pregnancy: The emerging role of relaxin. Am. J. Physiol. 301, R267-R275
4. Robb, A.O. et al. (2009) Influence of the menstrual cycle: Pregnancy, and preeclampsia on arterial stiffness. Hypertension 53, 952-958
5. Chapman, A.B. et al. (1997) Systemic and renal hemodynamic changes in the luteal phase of the menstrual cycle mimic early pregnancy. Am. J. Physiol. 273, F777-F782
6. Bosio, P.M. et al. (1999) Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet. Gynecol. 94, 978-984
7. Easterling, T.R. et al. (1990) Maternal hemodynamics in normal and preeclamptic pregnancies: A longitudinal study. Obstet. Gynecol. 76, 1061- 1069
8. Vasapollo, B. et al. (2004) Abnormal maternal cardiac function precedes the clinical manifestation of fetal growth restriction. Ultrasound Obstet. Gynecol. 24, 23-29
9. De Paco, C. et al. (2008) Maternal cardiac output between 11 and 13 weeks of gestation in the prediction of preeclampsia and small for gestational age. Obstet. Gynecol. 111 (Pt 1), 292-300
10. Salas, S.P. et al. (2006) Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension 47, 203-208
11. Conrad, K.P. et al. (2009) . In The kidney in normal pregnancy and preeclampsia, in Chesley's hypertensive disorders in pregnancy (. In The kidney in normal pregnancy and preeclampsia, in Chesley's hypertensive disorders in pregnancy (Lindheimer, M.D., . In The kidney in normal pregnancy and preeclampsia, in Chesley's hypertensive disorders in pregnancy (Roberts, J.M., Cunningham, F.G., eds), pp. 297-334, Elsevier
12. Maynard, S.E. et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction: Hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649-658
13. Li, Z. et al. (2007) Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50, 686-692
14. Mateus, J. et al. (2011) Endothelial growth factor therapy improves preeclampsia-like manifestations in a murine model induced by overexpression of sVEGFR-1. Am. J. Physiol. 301, H1781-H1787
15. Thadhani, R. et al. (2011) Pilot Study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia/clinical perspective. Circulation 124, 940-950
16. Kroeze, W.K. et al. (2003) G-protein-coupled receptors at a glance. J. Cell Sci. 116, 4867-4869
17. Overington, J.P. et al. (2006) How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996
18. Roh, J. et al. (2004) Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J. Biol. Chem. 279, 7264-7274
19. Chauhan, M. et al. (2011) Potential role of intermedin/adrenomedullin 2 in early embryonic development in rats. Regul. Pept. 170, 65-71
20. Dong, Y-L. et al. (2004) Involvement of calcitonin gene-related peptide in control of human fetoplacental vascular tone. Am. J. Physiol. 286, H230- H239
21. Brain, S.D. and Grant, A.D. (2004) Vascular actions of calcitonin generelated peptide and adrenomedullin. Physiol. Rev. 84, 903-934
22. Uddman, R. et al. (1986) Calcitonin gene-related peptide (CGRP): Perivascular distribution and vasodilatory effects. Regul. Pept. 15, 1-23
23. Stevenson, J.C. et al. (1986) Increased concentration of circulating calcitonin gene related peptide during normal human pregnancy. Br. Med. J. (Clin. Res. Ed.) 293, 1329-1330
24. Gangula, P.R.R. et al. (2000) Pregnancy and sex steroid hormones enhance circulating calcitonin gene-related peptide concentrations in rats. Hum. Reprod. 15, 949-953
25. Yallampalli, C. and Wimalawansa, S.J. (1998) Calcitonin gene-related peptide (CGRP) is a mediator of vascular adaptations during hypertension in pregnancy. Trends Endocrinol. Metab. 9, 113-117
26. Dong, Y.L. et al. (2005) Evidence for decreased calcitonin gene-related peptide (CGRP) receptors and compromised responsiveness to CGRP of fetoplacental vessels in preeclamptic pregnancies. J. Clin. Endocrinol. Metab. 90, 2336-2343
27. Dong, Y.L. et al. (2006) Circulating calcitonin gene-related peptide and its placental origins in normotensive and preeclamptic pregnancies. Am. J. Obstet. Gynecol. 195, 1657-1667
28. Dong, Y.L. et al. (2007) Calcitonin gene-related peptide (CALCA) is a proangiogenic growth factor in the human placental development. Biol. Reprod. 76, 892-899
29. Minamino, N. et al. (2002) Regulation of adrenomedullin expression and release. Microsc. Res. Tech. 57, 28-39
30. Hayashi, Y. et al. (2005) Circulating mature adrenomedullin is related to blood volume in full-term pregnancy. Anesth. Analg. 101, 1816-1820
31. Minegishi, T. et al. (1999) Adrenomedullin and atrial natriuretic peptide concentrations in normal pregnancy and pre-eclampsia. Mol. Hum. Reprod. 5, 767-770
32. Kobayashi, K. et al. (2000) Immunoreactive adrenomedullin (AM) concentration in maternal plasma during human pregnancy and AM expression in placenta. Eur. J. Endocrinol. 142, 683-687
33. Di Iorio, R. et al. (2003) Adrenomedullin in perinatal medicine. Regul. Pept. 112, 103-113
34. Jerat, S. and Kaufman, S. (1998) Effect of pregnancy and steroid hormones on plasma adrenomedullin levels in the rat. Can. J. Physiol. Pharmacol., 76, 463-466.
35. Ross, G.R. and Yallampalli, C. (2007) Vascular hyperresponsiveness to adrenomedullin during pregnancy is associated with increased generation of cyclic nucleotides in rat mesenteric artery. Biol. Reprod. 76, 118-123
36. Makino, I. et al. (1999) Adrenomedullin attenuates the hypertension in hypertensive pregnant rats induced by N(G)-nitro-L-arginine methyl ester. Eur. J. Pharmacol. 371, 159-167
37. Witlin, A.G. et al. (2003) Adrenomedullin requires an intact nitric oxide system to function as an endogenous vasodilator in rat gestation. Hypertens. Pregnancy 22, 9-24
38. Caron, K.M. and Smithies, O. (2001) Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc. Natl. Acad. Sci. U.S.A. 98, 615-619
39. Li, M. et al. (2006) Reduced maternal expression of adrenomedullin disrupts fertility: Placentation, and fetal growth in mice. J. Clin. Invest. 116, 2653-2662
40. Witlin, A.G. et al. (2002) Placental and fetal growth and development in late rat gestation is dependent on adrenomedullin. Biol. Reprod. 67, 1025- 1031
41. Penchalaneni, J. et al. (2004) Adrenomedullin antagonist treatment during early gestation in rats causes fetoplacental growth restriction through apoptosis. Biol. Reprod. 71, 1475-1483
42. Ross, G.R. et al. (2010) Adrenomedullin relaxes rat uterine artery: mechanisms and influence of pregnancy and estradiol. Endocrinology 151, 4485-4493
43. Carey, R.M. and Padia, S.H. (2008) Angiotensin AT2 receptors: Control of renal sodium excretion and blood pressure. Trends Endocrinol. Metab. 19, 84-87
44. Gant, N.F. et al. (1973) A study of angiotensin II pressor response throughout primigravid pregnancy. J. Clin. Invest. 52, 2682-2689
45. Hanssens, M.L. et al. (1991) Angiotensin II levels in hypertensive and normotensive pregnancies. Br. J. Obstet. Gynaecol. 98, 155-161
46. AbdAlla, S. et al. (2001) The angiotensin II AT2 receptor is an AT1 receptor antagonist. J. Biol. Chem. 276, 39721-39726
47. Carey, L.C. and Rose, J.C. (2011) The midgestational maternal blood pressure decline is absent in mice lacking expression of the angiotensin II AT2 receptor. J. Renin Angiotensin Aldosterone Syst. 12, 29-35
48. Chen, K. et al. (2007) The importance of angiotensin II subtype receptors for blood pressure control during mouse pregnancy. Reprod. Sci. 14, 694-704
49. Takeda-Matsubara, Y. et al. (2004) Roles of angiotensin type 1 and 2 receptors in pregnancy-associated blood pressure change. Am. J. Hypertens. 17, 684-689
50. Iacono, A. et al. (2009) Maternal adaptation in pregnant hypertensive rats: Improvement of vascular and inflammatory variables and oxidative damage in the kidney. Am. J. Hypertens. 22, 777-783
51. Pulgar, V.M. et al. (2011) Role of the AT2 receptor in modulating the angiotensin II contractile response of the uterine artery at mid-gestation. J. Renin Angiotensin Aldosterone Syst. 12, 176-183
52. Benoit, C. et al. (2008) Contractility of placental vascular smooth muscle cells in response to stimuli produced by the placenta: Roles of ACE vs. non- ACE and AT1 vs. AT2 in placental vessel cells. Placenta 29, 503-509
53. AbdAlla, S. et al. (2001) Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat. Med. 7, 1003-1009
54. Hansen, J.L. et al. (2009) Lack of evidence for AT1R/B2R heterodimerization in COS-7, HEK293, and NIH3T3 cells: How common is the AT1R/B2R heterodimer? J. Biol. Chem. 284, 1831-1839
55. Santos, R.A. et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100, 8258-8263
56. Valdes, G. et al. (2001) Urinary vasodilator and vasoconstrictor angiotensins during menstrual cycle: Pregnancy, and lactation. Endocrine 16, 117-122
57. Conrad, K.P. (2010) Unveiling the vasodilatory actions and mechanisms of relaxin. Hypertension 56, 2-9
58. Merrill, D.C. et al. (2002) Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine 18, 239-245
59. Neves, L.A. et al. (2003) Pregnancy enhances the angiotensin (Ang)-(1-7) vasodilator response in mesenteric arteries and increases the renal concentration and urinary excretion of Ang-(1-7). Endocrinology 144, 3338-3343
60. Wallukat, G. et al. (1999) Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 103, 945-952
61. LaMarca, B. et al. (2008) Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor a in pregnant rats. Hypertension 52, 1168-1172
62. LaMarca, B. et al. (2011) Hypertension in response to placental ischemia during pregnancy: Role of B lymphocytes. Hypertension 57, 865-871
63. LaMarca, B. et al. (2009) Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: Role of endothelin-1. Hypertension 54, 905-909
64. Parrish, M.R. et al. (2011) Hypertension in response to AT1-AA: Role of reactive oxygen species in pregnancy-induced hypertension. Am. J. Hypertens. 24, 835-840
65. Parrish, M.R. et al. (2010) The effect of immune factors: Tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am. J. Hypertens. 23, 911-916
66. Edwards, D.L. et al. (1996) Long-term nitric oxide blockade in the pregnant rat: Effects on blood pressure and plasma levels of endothelin-1. Am. J. Obstet. Gynecol. 175, 484-488
67. Wenzel, K. et al. (2011) Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension 58, 77-84
68. Irani, R.A. et al. (2010) Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factoralpha signaling. Hypertension 55, 1246-1253
69. Zhou, C.C. et al. (2011) Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J. Immunol. 186, 6024-6034
70. Herse, F. et al. (2009) Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension 53, 393-398
71. Siddiqui, A.H. et al. (2010) Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: Correlation with disease severity. Hypertension 55, 386-393
72. Leanos-Miranda, A. et al. (2010) Stimulating autoantibodies against the angiotensin II type 1 receptor are not associated with preeclampsia in Mexican-Mestizo women. J. Hypertens. 28, 834-841
73. Stepan, H. et al. (2006) Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J. Clin. Endocrinol. Metab. 91, 2424-2427
74. Stepan, H. and Walther, T. (2007) Questionable role of the angiotensin II receptor subtype 1 autoantibody in the pathogenesis of preeclampsia. Hypertension 50, e3
75. Walther, T. et al. (2005) Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension 46, 1275-1279
76. Jensen, F. et al. (2012) CD19+ CD5+ cells as indicators of preeclampsia. Hypertension 59, 861-868
77. Martin, J.N. et al. (1994) Plasma exchange for preeclampsia: II. Unsuccessful antepartum utilization for severe preeclampsia with or without hellp syndrome. J. Clin. Apheresis 9, 155-161
78. McGuane, J.T. et al. (2011) Relaxin Induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 152, 2786-2796
79. Sherwood, O.D. and Relaxin, (1994) . In The Physiology of Reproduction (. In The Physiology of Reproduction (Knobil, E. and Neill, J.D., eds), pp. 861- 1009, Raven Press
80. Conrad, K.P. (2011) Emerging role of relaxin in the maternal adaptations to normal pregnancy: Implications for preeclampsia. Semin. Nephrol. 31, 15-32
81. McGuane, J.T. et al. (2009) Role of relaxin in maternal systemic and renal vascular adaptations during gestation. Ann. N. Y. Acad. Sci. 1160, 304-312
82. Smith, M.C. et al. (2006) Relaxin has a role in establishing a renal response in pregnancy. Fertil. Steril. 86, 253-255
83. Danielson, L.A. et al. (1999) Relaxin is a potent renal vasodilator in conscious rats. J. Clin. Invest. 103, 525-533
84. Danielson, L.A. et al. (2000) Impact of gender and endothelin on renal vasodilation and hyperfiltration induced by relaxin in conscious rats. Am. J. Physiol. 279, R1298-R1304
85. Danielson, L.A. and Conrad, K.P. (1995) Acute blockade of nitric oxide synthase inhibits renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats. J. Clin. Invest. 96, 482-490
86. Conrad, K.P. et al. (1999) Endothelin mediates renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats. Am. J. Physiol. 276 (Pt 2), F767-F776
87. Jeyabalan, A. et al. (2003) Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation: Hyperfiltration, and reduced myogenic reactivity of small arteries. Circ. Res. 93, 1249-1257
88. Fernandez-Patron, C. et al. (1999) Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ. Res. 85, 906-911
89. Gandley, R.E. et al. (2001) Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats. Am. J. Physiol. 280, R1-R7
90. Novak, J. et al. (2002) Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats. Am. J. Physiol. 283, R349-R355
91. McGuane, J.T. et al. (2011) Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension 57, 1151-1160
92. Conrad, K.P. et al. (2004) Relaxin modifies systemic arterial resistance and compliance in conscious: Nonpregnant rats. Endocrinology 145, 3289-3296
93. Debrah, D.O. et al. (2011) Relaxin regulates vascular wall remodeling and passive mechanical properties in mice. J. Appl. Physiol. 111, 260-271
94. Segal, M.S. et al. (2012) Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. Blood 119, 629-636
95. Luppi, P. et al. (2010) Maternal Circulating CD34+ VEGFR-2+ and CD133+ VEGFR-2+ progenitor cells increase during normal pregnancy but are reduced in women with preeclampsia. Reprod. Sci. 17, 643-652
96. Conrad, K.P. and Colpoys, M.C. (1986) Evidence against the hypothesis that prostaglandins are the vasodepressor agents of pregnancy. Serial studies in chronically instrumented: Conscious rats. J. Clin. Invest. 77, 236- 245
97. Debrah, D.O. et al. (2005) Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension 46, 745-750
98. Podymow, T. and August, P. (2008) Update on the use of antihypertensive drugs in pregnancy. Hypertension 51, 960-969
99. Jeyabalan, A. et al. (2009) Low relaxin concentrations in the first trimester are associated with increased risk of developing preeclampsia. Reprod. Sci. 16 (Suppl.), 101A